Cantitate/Preț
Produs
Total produse
Vezi coșul
Proteinkinase Inhibitors de Stefan Laufer

Proteinkinase Inhibitors: Topics in Medicinal Chemistry, cartea 36

Editat de Stefan Laufer
en Limba Engleză Paperback – 24 mar 2022
This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book.
Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.

Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 88863 lei  6-8 săpt.
  Springer International Publishing – 24 mar 2022 88863 lei  6-8 săpt.
Hardback (1) 74286 lei  18-23 zile +6403 lei  6-12 zile
  Springer International Publishing – 24 mar 2021 74286 lei  18-23 zile +6403 lei  6-12 zile

Din seria Topics in Medicinal Chemistry

Preț: 88863 lei

Preț vechi: 108368 lei
-18% Nou

Puncte Express: 1333
Preț estimativ în valută:
17004€ • 18528$ • 14328£

Carte tipărită la comandă

Livrare economică 24 aprilie-08 mai

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783030681821
ISBN-10: 3030681823
Ilustrații: VII, 256 p. 1 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.38 kg
Ediția:1st ed. 2021
Editura: Springer International Publishing
Colecția Springer
Seria Topics in Medicinal Chemistry

Locul publicării:Cham, Switzerland

Cuprins

ProteinKinase-Inhibitors: A Story of Success.- Function, Structure and Topology of Proteinkinases.- Molecular Modelling.- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR.- Achieving high level of selectivity for kinase inhibitors.- Inhibitors of c-Jun N-terminal kinase 3.- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook.- Covalent Janus Kinase 3 Inhibitors.

Notă biografică

Stefan Laufer is a Professor of Pharmaceutical/Medicinal Chemistry at Tuebingen University, Germany, and he had previously worked for 10 years in the Pharmaceutical Industry. His research interests are anti-inflammatory and cancer drug discovery with various eicosanoid (COX-1,2,3, LOXs, mPGES1, cPLA2) and protein kinase targets (p38, JAKs, JNKs, CK1d, mtEGRFs). Three compounds from his lab entered clinical development phases. Dr. Laufer chairs the ICEPHA (Interfaculty Center for Pharmacogenomics and Drug Research) and TüCADD, Tuebingen Center for Academic Drug Discovery. As part of this work, a proprietary kinase inhibitor collection is established (TüKIC, 10.000 cpds). He authored more than 500 publications, 14 books/bookchapters, and is inventor in 42 patent families.

Textul de pe ultima copertă

This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book.

Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.

Caracteristici

Reviews proteinkinase inhibitors Exploits kinase inhibitors for cancer treatment Offers an authoritative perspective from industry and academia